---

name: alert-system description: | Automated alert system for key events in drug discovery. Use for tracking competitor milestones, clinical trial updates, regulatory decisions, and publications of interest.

Keywords: alerts, monitoring, tracking, notifications, competitive intelligence category: Intelligence tags: [alerts, monitoring, notifications, tracking] version: 1.0.0 author: Drug Discovery Team dependencies:

• clinicaltrials-api
• fda-api
• pubmed-api

---

Alert System Skill

Automated monitoring and alerting for drug discovery intelligence.

Quick Start

Copy/alerts --create --target "EGFR inhibitors" --events clinical,fda
/alerts --list
/alerts --check my-alert

What's Included

Alert Configuration

Copyname: EGFR Competitive Alerts
description: Monitor EGFR inhibitor landscape

targets:
  - EGFR
  - Exon 19 deletion
  - T790M
  - C797S

competitors:
  - AstraZeneca
  - Johnson & Johnson
  - Roche

events:
  - clinical_trial_updates
  - regulatory_approvals
  - publications
  - patent_filings

filters:
  phase: [2, 3]
  countries: [US, EU, CN, JP]
  minimum_significance: high

notifications:
  email: user@example.com
  frequency: weekly
  format: summary

Output Structure

Copy# Alert Report: EGFR Landscape (Weekly)

## Summary
| Alert Type | New | Total |
|------------|-----|-------|
| Clinical Updates | 3 | 127 |
| Publications | 12 | 456 |
| Regulatory | 1 | 23 |
| Patent Filings | 5 | 89 |

## Clinical Trial Updates

### New Trials
| NCT ID | Sponsor | Phase | Indication | Status |
|--------|---------|-------|------------|--------|
| NCT01234567 | AstraZeneca | 3 | NSCLC | Recruiting |
| NCT01234568 | Johnson & Johnson | 2 | NSCLC | Not recruiting |

### Status Changes
| NCT ID | Previous | Current | Date |
|--------|----------|---------|------|
| NCT07890123 | Recruiting | Active, not recruiting | 2024-12-10 |

## Key Publications

1. **Fourth-generation EGFR inhibitors targeting C797S**
   - Journal: Nature Cancer
   - Date: 2024-12-08
   - Authors: Zhang et al.
   - Impact: Novel scaffold for resistance

2. **Combination therapy: EGFR + MET inhibition**
   - Journal: Lancet Oncology
   - Date: 2024-12-05
   - Authors: Smith et al.
   - Impact: Positive Phase 2 results

## Regulatory Updates

### FDA Actions
| Date | Sponsor | Action | Drug |
|------|---------|--------|------|
| 2024-12-12 | AstraZeneca | Approval | Tagrisso (adjuvant) |

## Patent Filings

### New Patents
| Date | Assignee | Title | Patent No. |
|------|----------|-------|------------|
| 2024-12-10 | Merck | EGFR C797S inhibitors | US2024/XXX |
| 2024-12-08 | Roche | Antibody-drug conjugate | EPXXX |

## Recommendations

**Action Items**:
1. Review new C797S inhibitor paper - assess differentiation
2. Monitor AstraZeneca adjuvant approval impact
3. Investigate Merck's new patent - potential FTO issue

Event Types

Running Scripts

Copy# Create new alert
python scripts/alert_system.py --create my-alert --target "EGFR"

# Check for updates
python scripts/alert_system.py --check my-alert

# List all alerts
python scripts/alert_system.py --list

# Export alert history
python scripts/alert_system.py --export my-alert --format csv

Requirements

Copypip install requests schedule

# For persistence
pip install sqlalchemy

Reference

• reference/alert-types.md - Alert type reference
• reference/data-sources.md - Data source configuration
• reference/notifications.md - Notification setup

Best Practices

1. Set specific targets: Narrower = fewer false positives
2. Use appropriate frequency: Daily for high-priority, weekly for others
3. Review regularly: Alerts need human interpretation
4. Adjust filters: Refine based on signal-to-noise
5. Document actions: Track alert-driven decisions

Common Pitfalls

Alert Frequency Guidelines